5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Desmopressin – sublingual tablets

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Desmopressin – sublingual tablets

Desmopressin – sublingual tablets

Class : C!

Show all info

Print

Contact us

  1. Juul KV, Klein BM, Sandstrom R, Erichsen L, Nørgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):1116-22.

  2. Nocdurna (desmopressin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2021-05-03, cited 2023-11-16]

  3. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441-7.

  4. Nocdurna (desmopressin). EPAR - Public assessment report. European Medicines Agency (EMA) [updated 2015-03-26, 2023-11-16]

  5. Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2013;32(4):363-70.

  6. Juul KV, Klein BM, Nørgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013;32(4):363-70.

  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Juul KV, Klein BM, Sandstrom R, Erichsen L, Nørgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):1116-22.
  2. Nocdurna (desmopressin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2021-05-03, cited 2023-11-16]
  3. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441-7.
  4. Nocdurna (desmopressin). EPAR - Public assessment report. European Medicines Agency (EMA) [updated 2015-03-26, 2023-11-16]
  5. Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2013;32(4):363-70.
  6. Juul KV, Klein BM, Nørgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013;32(4):363-70.
  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]